/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?
Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos · Oct 5, 2026

Experts debate adjuvant therapy for high-risk UTUC, weighing ctDNA surveillance against gem-carbo and EV-pembro amid limited trial data.

Adjuvant Checkpoint Inhibitors Consistently Underperform in Upper Tract Urothelial Cancer Subsets

Despite broad approvals based on intent-to-treat populations, adjuvant immune checkpoint inhibitors have shown hazard ratios above 1.0 for both disease-free and overall survival in upper tract subsets across trials like CheckMate 274 (HR 1.23) and IMvigor010. Consequently, oncologists hesitate to extrapolate bladder cancer trial outcomes to upper tract disease, as dedicated evidence demonstrating a therapeutic benefit in this anatomical subgroup remains absent.

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC? thumbnail

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos·a month ago

ctDNA Clearance Endpoints Should Replace Multi-Year Phase III UTUC Trials

Rare malignancies like upper tract urothelial carcinoma struggle to enroll sufficiently powered randomized trials, taking up to eight years to report overall survival. Instead of waiting for traditional phase III registrational designs, experts advocate conducting smaller, 100-patient non-traditional studies using ctDNA clearance as an early surrogate endpoint. This strategy enables rapid evaluation of novel antibody-drug conjugate and immunotherapy combinations to inform clinical care far sooner.

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC? thumbnail

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos·a month ago

Carboplatin Lacks Strong Evidence in Perioperative Upper Tract Urothelial Carcinoma

Although the POUT trial established adjuvant platinum chemotherapy for upper tract urothelial cancer, the carboplatin subgroup yielded a weaker overall survival hazard ratio of 0.86 with drifting disease-free survival. Because carboplatin historically failed in neoadjuvant bladder cancer, guidelines like ESMO restrict recommendations to cisplatin, leaving cisplatin-ineligible patients facing substantial toxicity—44% grade 3 or 4 adverse events in POUT—without convincing survival data.

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC? thumbnail

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos·a month ago

Postoperative ctDNA Status Redefines UTUC Risk Better Than Pathologic Staging

Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC? thumbnail

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos·a month ago

PD-L1 Biomarker Status Should Not Guide Adjuvant Nivolumab in Upper Tract Disease

Even though CheckMate 274 showed improved disease-free survival in PD-L1-positive patients overall, oncologists caution against relying on PD-L1 to prescribe adjuvant nivolumab for upper tract tumors. Across urothelial cancer trials—including frontline metastatic settings—the PD-L1 biomarker has repeatedly failed to predict outcomes reliably. Furthermore, regulatory labels do not mandate PD-L1 testing, making it an unreliable surrogate for overcoming negative upper tract checkpoint inhibitor performance.

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC? thumbnail

Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

The Uromigos·a month ago